Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$39.19 USD

39.19
1,019,400

+0.73 (1.90%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks News

Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU

Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.

    Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up

    Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.

      Ionis Pharmaceuticals (IONS) Misses on Q2 Earnings

      Ionis Pharmaceuticals' (IONS) reported loss of 9 cents including stock based compensation was wider than expectation. However, sales beat estimates.

        Why Earnings Season Could Be Great for Ionis (IONS)

        Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

          Is a Beat in Store for Ionis (IONS) This Earnings Season?

          Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.

            Ironwood (IRWD) Reports Positive Data on Reflux Candidate

            Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.

              Why is Alnylam's (ALNY) Stock Close to 100% this Year?

              Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.

                Biogen/Ionis Spinraza Granted Marketing Authorization in EU

                Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.

                  Biogen's Fampyra Conditional Approval Converted to Standard

                  Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.

                    Ionis (IONS) Stock Falls Despite Positive Inotersen Data

                    Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.

                      Biogen (BIIB) Buys Stroke Candidate Cirara for $120M

                      Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals' phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI).

                        Madeleine Johnson headshot

                        Here's Why Shares of Ionis Pharma (IONS) are Falling Today

                        On Monday, shares of Ionis Pharmaceuticals Inc. (IONS) are falling, down about 10% in morning trading after the company announced results from its 15-month long Phase 3 Neuro-TTR Study of its drug Inotersen (IONIS-TTRrx).

                          Indrajit Bandyopadhyay headshot

                          Ionis Pharmaceuticals (IONS) Beats on Q1 Earnings

                          Ionis reported earnings of 3 cents including stock based compensation which surpassed the Zacks Consensus Estimate of loss of 4 cents

                            4 Drug Stocks Poised to Beat this Earnings Season

                            M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

                              What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

                              Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

                                Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?

                                Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11

                                  Why Ionis (IONS) Might Surprise This Earnings Season

                                  Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                    What's in the Cards for Ionis (IONS) this Earnings Season?

                                    Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let's see how things are shaping up for this announcement.

                                      Ionis Pharma Lipid Disorder Candidate Positive in Phase III

                                      Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.

                                        Ionis Pharmaceuticals (IONS) Beats on Q4 Earnings

                                        Ionis reported earnings of 21 cents including stock based compensation. However, excluding stock based compensation the company reported earnings of 33 cents that surpassed the Zacks Consensus Estimate of loss of 20 cents.

                                          Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

                                          Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

                                            Ionis Pharmaceuticals (IONS) Sees Hammer Chart Pattern: Time to Buy?

                                            Ionis Pharmaceuticals, Inc. (IONS) has been struggling lately, but the selling pressure may be coming to an end soon

                                              Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017

                                              We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.

                                                Biogen (BIIB) Presents Positive Phase III Data on Spinraza

                                                Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).

                                                  Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments

                                                  Ionis (IONS) entered into a collaboration agreement with Novartis (NVS) for the development and commercialization of AKCEA-APO(a)-L and AKCEA-APOCIII-L.